|
시장보고서
상품코드
2107763
간섬유증 치료 시장 : 치료법별, 질환별, 유통 채널별, 지역별Liver Fibrosis Treatment Market, By Treatment Type, By Condition, By Distribution Channel, By Geography |
||||||
간섬유증 치료 시장은 2026년에 226억 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 470억 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 11%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 226억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 11.00% | 2033년 시장 규모 예측 : | 470억 달러 |
간섬유증이란 대부분의 만성 간 질환에서 발생하는 콜라겐을 포함한 세포외 기질 단백질의 과도한 축적을 말합니다. 진행된 간 섬유화는 간경변, 간부전, 문맥고혈압을 유발하며, 많은 경우 간 이식이 필요합니다. 간 섬유화는 간에 반복적이거나 지속적인 손상이 특징이며, 그 결과 간 내에 비정상적인 양의 흉터 조직이 생깁니다. 섬유화 자체로는 증상이 나타나지 않지만, 심한 흉터 형성은 간경변을 유발하여 추가적인 증상이 나타나는 원인이 됩니다. 만성 간 질환의 중증도를 판정하기 위해 의료진은 혈액 검사 및 영상 검사를 시행하고, 필요에 따라 간 생검을 시행합니다. 간섬유증의 치료법으로는 의료진이 원인 치료에 중점을 둡니다. 이를 통해 대부분의 경우 간의 추가적인 섬유화를 막거나 지연시켜 병세 개선으로 이어집니다. 간섬유증의 주요 치료법으로는 항바이러스제 사용, 담관 폐쇄의 제거 또는 용해, 알코올 섭취량 감소 등 생활 습관 개선, 비만 및 과체중 관리, 그리고 비알코올성 지방간 질환 환자의 혈당 및 지질 수치 관리 등이 포함됩니다.
시장 역학
고지방 식단을 섭취하는 인구의 증가에 따라 비알코올성 지방간염(NASH)의 유병률은 예측 기간 중 증가할 것으로 예상됩니다. 비만 및 당뇨병의 확산, 간섬유증, 그리고 NASH의 증가가 시장 성장을 촉진할 것으로 예상되며, 주요 기업은 이러한 질환의 치료법 개발에 주력하고 있습니다. 예를 들어 2022년 4월 미국 국립생물공학정보센터(NCBI)에 따르면 지난 10년간 미국내 NASH 유병률은 현저히 증가했습니다. 이는 위험 요인의 유병률 증가뿐만 아니라 이 질환에 대한 의식의 향상와도 관련이 있는 것으로 보입니다. 2021년 NASH 환자의 성별 분포는 여성이 54.1%, 남성이 45.9%였습니다. 전문가들의 추정에 따르면 미국 성인의 약 24%가 비알코올성 지방간 질환(NAFLD)을 앓고 있으며, 약 1.5%에서 6.5%가 NASH를 앓고 있는 것으로 알려져 있습니다. 비알코올성 지방간 질환(NAFLD)은 단순 지방간의 상태이며, 이 상태에 있는 사람의 20%에서 30%가 비알코올성 지방간염(NASH)으로 진행됩니다. 또한 20%에서 30%의 환자는 더 진행된 비알코올성 지방간염(NASH) 섬유증으로 진행되며, 최종 단계는 비알코올성 지방간염(NASH) 간경변이 됩니다.
본 조사의 주요 특징
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 해설하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트도 제공합니다.
- 본 조사에서는 다음 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략)를 바탕으로 전 세계 간섬유증 치료 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서에서 얻을 수 있는 인사이트를 통해 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 본 ‘전 세계 간섬유증 치료 시장’ 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 간섬유증 치료 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 원활한 의사결정을 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 개요
제3장 시장 역학·규제·동향 분석
제4장 세계의 간섬유증 치료 시장 : 치료 유형별, 2021-2033년
제5장 세계의 간섬유증 치료 시장 : 질환별, 2021-2033년
제6장 세계의 간섬유증 치료 시장 : 유통 채널별, 2021-2033년
제7장 세계의 간섬유증 치료 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSALiver Fibrosis Treatment Market is estimated to be valued at USD 22.6 Bn in 2026 and is expected to reach USD 47 Bn by 2033, growing at a compound annual growth rate (CAGR) of 11% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 22.6 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 11.00% | 2033 Value Projection: | USD 47 Bn |
Liver fibrosis is the excessive accumulation of extracellular matrix proteins including collagen that occurs in most types of chronic liver diseases. Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation. Liver fibrosis is characterized by repeated or continuous damage to liver resulting in an abnormally large amount of scar tissue in the liver. Fibrosis does not show any symptoms, however severe scarring results into cirrhosis, which further leads to cause symptoms. To detect the severity of chronic liver disease, healthcare professionals conduct blood and imaging test, followed by liver biopsy, if required. In the possible treatment options for liver fibrosis, healthcare professionals focus on treating the cause, which often stops and slows down further scarring of liver and results in improvement of the condition. The possible treatment options for liver fibrosis include use of antiviral drugs, removal or dissolution of a blockage in the bile ducts, lifestyle changes such as lower consumption of alcohol, control regime for obesity and overweight, and controlling blood sugar & lipid levels in people with nonalcoholic fatty liver.
Market Dynamics
The underlining prevalence cases of Non-alcoholic Steatohepatitis (NASH) are expected to increase over the forecast period with increasing amount of population consuming high fat diet. Increasing obesity and diabetes epidemics, liver fibrosis, and NASH are expected to drive market growth, as key players are focused on developing treatment for these disorders. For instance, in April 2022, according to National Center for Biotechnology Information, the prevalence of NASH has significantly increased in the U.S. in the last decade. This is likely related to the increased prevalence of risk factors as well as increased awareness of the disease. The proportion of patients with NASH by gender was 54.1% female verses 45.9% male in 2021. Experts estimate about 24% of U.S. adults have Non-alcoholic fatty liver disease (NAFLD) and about 1.5% to 6.5% of U.S. adults have NASH. Non-alcoholic fatty liver disease (NAFLD) states as simple fat, which impacts on 20% to 30% of those individuals who progress to nonalcoholic steatohepatitis (NASH). Another 20% to 30% of individual's progress to more advanced Non-alcoholic Steatohepatitis (NASH) fibrosis, and the final stage is Non-alcoholic Steatohepatitis (NASH) cirrhosis.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global liver fibrosis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., FibroGen, Inc., and Pharmaxis Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global liver fibrosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global liver fibrosis treatment market
Market Segmentation
- By Treatment Type (Revenue, USD Bn, 2021-2033)
- Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
- ACE Inhibitors
- Hepatotropic Drug
- Others
- By Condition (Revenue, USD Bn, 2021-2033)
- Chronic Liver Diseases
- Hepatitis C
- Nonalcoholic Steatohepatitis
- By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospitals
- Specialty Clinics
- Others
- By Region (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb
- Johnson and Johnson
- Novartis AG
- Vertex Pharmaceuticals Incorporated
- Pfizer Inc.
- FibroGen, Inc.
- Pharmaxis Limited
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Condition
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Disease Type Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Liver Fibrosis Treatment Market, By Treatment Type, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- ACE Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Hepatotropic Drug
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
5. Global Liver Fibrosis Treatment Market, By Condition, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Chronic Liver Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Hepatitis C
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Nonalcoholic Steatohepatitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
6. Global Liver Fibrosis Treatment Market, By Distribution Channel, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
7. Global Liver Fibrosis Treatment Market, By Region, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Condition, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Condition, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Condition, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Condition, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Condition, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Condition, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Johnson and Johnson
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Vertex Pharmaceuticals Incorporated
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- FibroGen, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pharmaxis Limited
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Gilead Sciences, Inc.
- Analyst Views
9. Section
- References
- Research Methodology
- About Us
